Results 11 to 20 of about 244 (126)

MicroRNA Expression in High-Grade B-Cell Lymphoma With 11q Aberration. [PDF]

Genes Chromosomes Cancer
ABSTRACT Mature aggressive B‐cell lymphomas, such as Burkitt lymphoma (BL) and Diffuse large B‐cell lymphoma (DLBCL), show variations in microRNA (miRNA) expression. The entity of High‐grade B‐cell lymphoma with 11q aberration (HGBCL‐11q) shares several biological features with both BL and DLBCL but data on its miRNA expression profile are yet scarce ...
Di Stefano G, Fischer A, Chteinberg E, Bens S, Wagener R, Abramov D, Adam P, Bernhart SH, Borkhardt A, Burkhardt B, Del-Val C, Frühwald MC, Guazzo R, Hoell JI, Hummel M, Horn H, Klapper W, Krugmann J, Kurz KS, Lazzi S, Louissaint AJ, Mottok A, Oschlies I, Santi R, Schafernak K, Staiger AM, Zhang Y, Rosenwald A, Trümper L, Leoncini L, Ott G, Siebert R.   +31 more
europepmc   +2 more sources

Goodbye flat lymphoma biology. [PDF]

FEBS Lett
Three‐dimensional (3D) biological systems have become key tools in lymphoma research, offering reliable in vitro and ex vivo platforms to explore pathogenesis and support precision medicine. This review highlights current 3D non‐Hodgkin lymphoma models, detailing their features, advantages, and limitations, and provides a broad perspective on future ...
Faria C, Dobaño-López C, Pérez-Galán P, Bezombes C.   +3 more
europepmc   +2 more sources

Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma. [PDF]

J Cell Mol Med, 2021
Abstract MYSM1 is a chromatin‐binding protein, widely investigated for its functions in haematopoiesis in human and mouse; however, its role in haematologic malignancies remains unexplored. Here, we investigate the cross‐talk between MYSM1 and oncogenic cMYC in the transcriptional regulation of genes encoding ribosomal proteins, and the implications of
Lin YH, Wang H, Fiore A, Förster M, Tung LT, Belle JI, Robert F, Pelletier J, Langlais D, Nijnik A.   +9 more
europepmc   +2 more sources

Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma. [PDF]

Cancer Med, 2020
Our study included 477 Burkitt Lymphoma (BL) patients with gastrointestinal involvement extracted from the SEER database between 2004 and 2015, 112 (23.5%) with the stomach and 365 (76.5%) with the intestine. We demonstrated that BL patients with gastric involvement had an inferior prognosis compared to those with intestinal involvement (5‐year OS 37.8%
Xie Y, Jia M, Shi J, Tao Y.
europepmc   +2 more sources

Mature B‐cell lymphomas in adolescents and young adults

eJHaem, Volume 4, Issue 4, Page 912-920, November 2023., 2023
Abstract Pediatric non‐Hodgkin lymphoma includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the US, compared to >60,000 cases of adult NHL annually. Improvements in survival in pediatric and adolescent mature B cell NHL over the past 5 decades align with the overall success of the cooperative trial model with ...
Nader Kim El‐Mallawany, Lisa Giulino‐Roth, John M. Burke, Michelle Hermiston, Carl E. Allen   +4 more
wiley   +1 more source

Infektionen mit Herpes‐simplex‐ und Varizella‐zoster‐Virus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 20, Issue 10, Page 1327-1353, October 2022., 2022
Zusammenfassung Humane Herpesviren gehören zu den DNA‐Viren und zählen zu den häufigsten Erregern viraler Infektionen beim Menschen. Nach der Primärinfektion mit einem dieser Viren kommt es typischerweise zur Latenz mit dem Potenzial späterer Reaktivierungen, die häufiger symptomatisch sind und zum Arztbesuch führen als die Primärinfektion.
Larissa Wilms, Katharina Weßollek, Theresa Barbara Peeters, Amir Sadegh Yazdi   +3 more
wiley   +1 more source

Paediatric Burkitt lymphoma patient‐derived xenografts capture disease characteristics over time and are a model for therapy

British Journal of Haematology, Volume 192, Issue 2, Page 354-365, January 2021., 2021
Summary Burkitt lymphoma (BL) accounts for almost two‐thirds of all B‐cell non‐Hodgkin lymphoma (B‐NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a ...
Sorcha Forde, Jamie D. Matthews, Leila Jahangiri, Liam C. Lee, Nina Prokoph, Tim I.M. Malcolm, Olivier T. Giger, Natalie Bell, Helen Blair, Aengus O'Marcaigh, Owen Smith, Lukas Kenner, Simon Bomken, Gladstone A. A. Burke, Suzanne D. Turner   +14 more
wiley   +1 more source

The EHA Research Roadmap: Malignant Lymphoid Diseases

, 2022
HemaSphere, Volume 6, Issue 6, June 2022.
Martin Dreyling, Marc André, Nicola Gökbuget, Hervé Tilly, Mats Jerkeman, John Gribben, Andrés Ferreri, Pierre Morel, Stephan Stilgenbauer, Christopher Fox, José Maria Ribera, Sonja Zweegman, Igor Aurer, Csaba Bödör, Birgit Burkhardt, Christian Buske, Maria Dollores Caballero, Elias Campo, Bjoern Chapuy, Andrew Davies, Laurence de Leval, Jeanette Doorduijn, Massimo Federico, Philippe Gaulard, Francesca Gay, Paolo Ghia, Kirsten Grønbæk, Hartmut Goldschmidt, Marie‐Jose Kersten, Barbara Kiesewetter, Judith Landman‐Parker, Steven Le Gouill, Georg Lenz, Sirpa Leppä, Armando Lopez‐Guillermo, Elizabeth Macintyre, Maria Victoria Mateos Mantega, Philippe Moreau, Carol Moreno, Bertrand Nadel, Jessica Okosun, Roger Owen, Sarka Pospisilova, Christiane Pott, Tadeusz Robak, Michelle Spina, Kostas Stamatopoulos, Jan Stary, Karin Tarte, Allessandra Tedeschi, Catherine Thieblemont, Ralf Ulrich Trappe, Lorenz H. Trümper, Gilles Salles   +53 more
wiley   +1 more source

Molecular mechanism of c‐Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma

Journal of Cellular and Molecular Medicine, Volume 24, Issue 12, Page 6704-6715, June 2020., 2020
Abstract Patients with relapsed/refractory Burkitt's lymphoma (BL) have a dismal prognosis. Current research efforts aim to increase cure rates by identifying high‐risk patients in need of more intensive or novel therapy. The 8q24 chromosomal translocation of the c‐Myc gene, a main molecular marker of BL, is related to the metabolism by regulating ...
Ting Li, Lili Song, Yingwen Zhang, Yali Han, Zhiyan Zhan, Zhou Xv, Yang Li, Yuejia Tang, Yi Yang, Siqi Wang, Shanshan Li, Liang Zheng, Yanxin Li, Yijin Gao   +13 more
wiley   +1 more source

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

British Journal of Haematology, Volume 188, Issue 5, Page 661-673, March 2020., 2020
Summary Rituximab is a standard treatment for non‐Hodgkin diffuse large B‐cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration‐related reactions (ARRs). MabRella was a phase IIIb trial to
Ricardo García‐Muñoz, Cristina Quero, Ernesto Pérez‐Persona, Abel Domingo‐García, Cristina Pérez‐López, Teresa Villaescusa‐de‐la‐Rosa, Ana M. Martínez‐Castro, José M. Arguiñano‐Pérez, Juan F. Parra‐Cuadrado, Carlos Panizo   +9 more
wiley   +1 more source